Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
42388-0023-37 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Oct. 3, 2018 In Use
42388-0023-46 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0023-57 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0024-26 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral April 25, 2016 In Use
42388-0024-37 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Feb. 27, 2019 In Use
42388-0024-46 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0024-57 42388-0024 Cabozantinib CABOMETYX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0025-26 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral April 25, 2016 In Use
42388-0025-37 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Feb. 27, 2019 In Use
42388-0025-46 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0025-57 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
00310-3512-60 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
00310-3512-95 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
69448-0014-63 69448-0014 LEUPROLIDE CAMCEVI 42.0 mg/.37g Hormonal Therapy GnRH Agonist Subcutaneous April 5, 2022 In Use
72851-0042-01 72851-0042 Leuprolide CAMCEVI 42.0 mg/mL Hormonal Therapy GnRH Agonist Subcutaneous Dec. 30, 2022 In Use
68001-0487-06 68001-0487 CAPECITABINE CAPECITABINE 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 22, 2021 In Use
68001-0488-07 68001-0488 CAPECITABINE CAPECITABINE 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 22, 2021 In Use
58468-7860-03 58468-7860 Vandetanib CAPRELSA 300.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Oral June 24, 2022 In Use
54288-0164-01 54288-0164 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0165-01 54288-0165 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0166-01 54288-0166 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
54288-0167-01 54288-0167 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 31, 2023 In Use
82511-0006-60 82511-0006 CARBOPLATIN CARBOPLATIN 600.0 mg/60mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 24, 2023 In Use
55150-0386-01 55150-0386 CARBOPLATIN CARBOPLATIN 600.0 mg/60mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 3, 2020 In Use
47781-0603-20 47781-0603 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous March 1, 2018 Aug. 1, 2019 No Longer Used

Found 10,000 results in 4 milliseconds — Export these results